AKT2 is a serine/threonine kinase that functions as a critical metabolic and developmental regulator with distinct tissue-specific roles. Primary function involves insulin-stimulated glucose uptake through GLUT4 translocation and regulation of adipocyte differentiation 1. AKT2 phosphorylates key substrates including C2CD5 to facilitate glucose transport [UniProt] and PITX2 to suppress myoblast differentiation by disrupting CCND1 mRNA stabilization [UniProt]. In hepatocytes, AKT2 phosphorylates CLK2 to suppress gluconeogenesis [UniProt]. The AKT2/SIRT5/TFEB pathway regulates lysosomal and mitochondrial function in retinal pigmented epithelium; aberrant AKT2 activation impairs TFEB-dependent autophagy, contributing to dry age-related macular degeneration 2. Disease relevance is substantial: AKT2 amplification or overexpression occurs in pancreatic, lung, and ovarian carcinomas, where it promotes proliferation, migration, and invasion through EMT activation and MMP upregulation 345. In lung adenocarcinoma, miR-124 suppresses AKT2 expression to inhibit tumor progression 5. AKT2 mutations cause familial partial lipodystrophy and diabetes [UniProt]. In esophageal squamous cell carcinoma, AKT2-phosphorylated CCTα drives phosphatidylcholine production, promoting FAK inhibitor resistance 6. AKT2 represents a promising therapeutic target across metabolic and malignant diseases.